

WFW ADVISES SARTORIUS ON €8.2M SERIES A FINANCING ROUND FOR CUREXSYS

14 DECEMBER 2020 • PRESS



Watson Farley & Williams (“WFW”) advised Sartorius AG (“Sartorius”) on a €8.2m Series A financing round for Curexsys GmbH (“Curexsys”), a Germany-based technology leader specialising in the emerging field of therapeutic exosomes, with Evotec SE investing alongside Sartorius.

Curexsys produces proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables Curexsys to overcome a key hurdle in exosome preparation, i.e. remaining antibodies in the final preparation. Curexsys was founded by Dr Herbert Stadler, a serial biotech entrepreneur, and Dr Jens Gruber, a former group leader of Medical RNA Biology who acts as the Curexsys’ Chief Scientific Officer.

Sartorius is an international life sciences company based in Göttingen, Germany. In addition to supplying pharmaceutical laboratory equipment worldwide, Sartorius is dedicated to accelerating medical discoveries and simplifying drug production.

The WFW Germany Corporate team that advised Sartorius was led by Frankfurt Partner Dr Christoph Naumann, supported by Frankfurt Associate Matthias Strecker. Counsel Torge Rademacher and Associate Desideria-Alexia Pohl (both Hamburg) advised on the IP law aspects of the financing round.

Christoph commented: “I’m delighted that we were able to help our client successfully close this financing round which enables Curexsys to accelerate the commercialisation of its exosome isolation technology. We are very pleased that our long-standing client Sartorius opted again for WFW to advise them”.

RELATED CONTACTS



TORGE RADEMACHER

COUNSEL • HAMBURG

T: +49 40 800 084 438

trademacher@wfw.com

MEDIA ENQUIRIES



WILL SALOMONE

T: +44 20 3036 9847

media@wfw.com

DISCLAIMER

Watson Farley & Williams is a sector specialist international law firm with a focus on the energy, infrastructure and transport sectors. With offices in Athens, Bangkok, Dubai, Dusseldorf, Frankfurt, Hamburg, Hanoi, Hong Kong, London, Madrid, Milan, Munich, New York, Paris, Rome, Seoul, Singapore, Sydney and Tokyo our 700+ lawyers work as integrated teams to provide practical, commercially focussed advice to our clients around the world.

All references to 'Watson Farley & Williams', 'WFW' and 'the firm' in this document mean Watson Farley & Williams LLP and/or its affiliated entities. Any reference to a 'partner' means a member of Watson Farley & Williams LLP, or a member, partner, employee or consultant with equivalent standing and qualification in WFW Affiliated Entities. A list of members of Watson Farley & Williams LLP and their professional qualifications is open to inspection on request.

Watson Farley & Williams LLP is a limited liability partnership registered in England and Wales with registered number OC312252. It is authorised and regulated by the Solicitors Regulation Authority and its members are solicitors or registered foreign lawyers.

The information provided in this publication (the "Information") is for general and illustrative purposes only and it is not intended to provide advice whether that advice is financial, legal, accounting, tax or any other type of advice, and should not be relied upon in that regard. While every reasonable effort is made to ensure that the Information provided is accurate at the time of publication, no representation or warranty, express or implied, is made as to the accuracy, timeliness, completeness, validity or currency of the Information and WFW assume no responsibility to you or any third party for the consequences of any errors or omissions. To the maximum extent permitted by law, WFW shall not be liable for indirect or consequential loss or damage, including without limitation any loss or damage whatsoever arising from any use of this publication or the Information.

This publication constitutes attorney advertising.